The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Extensions of BRUIN investigating pirtobrutinib combinations for time-limited CLL treatment
Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, New York, NY, gives an update on the BRUIN trial (NCT03740529), which found that patients with chronic lymphocytic leukemia (CLL) responded well to pirtobrutinib after a covalent BTK inhibitor. There are many extension studies that combine pirtobrutinib with other agents in a time-limited approach. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
SAB/Consultant/Honoraria: AbbVie, Adaptive Biosciences, Astra-Zeneca, Bei-Gene, Genentech,Genmab, Janssen, LOXO/Eli Lilly, Pharmacyclics
Institutional Research funding: AbbVie, Astra-Zeneca, BeiGene, Genentech, Genmab, LOXO/Eli Lilly, MingSight, Octapharma, Oncternal
